Although it is known that t-MNs have significantly lower frequencies of FLT3 and NPM1 mutations than de novo MNs [1, 14], such mutations may have an impact on the prognosis in some t-MN patients, especially those with NKs. The gene discussed is NPM1; the disease is therapy-related myeloid neoplasm.